William Shakespeare - Mar 1, 2023 Form 4 Insider Report for Theseus Pharmaceuticals, Inc. (THRX)

Role: President of Research and Development
Signature: /s/ Bradford Dahms - Attorney-in-Fact
Stock symbol: THRX
Transactions as of: Mar 1, 2023
Transactions value $: $0
Form type: 4
Date filed: 3/2/2023, 06:01 AM
Previous filing: Feb 21, 2023
Next filing: Nov 7, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	THRX	Restricted Stock Units	Award	$0	+21.3K		$0.00	21.3K	Mar 1, 2023	Common Stock	21.3K		Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.001, when vested.
F2	The RSUs are subject to a service-based vesting requirement, which shall be satisfied over a four-year period with 25% of the RSUs vesting on March 1, 2024 and 1/16th of the RSUs vesting quarterly thereafter, subject to the Reporting Person's continuous service with the issuer. The RSUs have no expiration date.

Remarks:

President of Research and Development